While the gut instinct is that patients prefer daily pills over injections, this preference flips when the injection is highly infrequent. For chronic conditions, a quarterly shot (four per year) is often viewed as more convenient and favorable by patients than the burden of a daily oral medication, challenging conventional wisdom on administration routes.

The on-body injector's fixed, flat-rate dosage simplifies clinical workflow and improves safety by eliminating the need for constant, error-prone dose recalculations based on patient weight changes, which is standard for many body surface area (BSA)-based cancer therapies.

Many firms view patient engagement as a compliance task that adds cost. However, data shows integrating patient experience into development from the start speeds up clinical trial recruitment and execution, reduces FDA amendments, and accelerates time-to-market, providing clear ROI.

The isatuximab on-body injector (OBI) is more than an in-clinic convenience; it represents a key technological step toward moving oncology treatment out of specialized centers. This could enable care closer to or even at patients' homes, particularly benefiting rural patients who face significant travel burdens.

Administering complex biologics at home via on-body devices can bridge significant healthcare disparities. This model can eliminate the physical, financial, and geographic barriers faced by patients in rural areas or those reliant on caregivers for transport to infusion centers.

Isatuximab previously lagged its competitor, daratumumab, which had a subcutaneous option for years. The new on-body injector (OBI) isn't just about catching up; its efficiency and high patient preference could shift treatment patterns, making it a significant competitive threat and altering its market position.

Eupraxia's technology is defined by its precision: delivering a stable, flat dose directly into target tissue for up to a year. This hyper-local approach mimics the stability of a continuous IV infusion, aiming to maximize efficacy while minimizing systemic side effects caused by the 'peaks and troughs' of conventional pills or injections.

A key trend in 2025's drug approvals is that "best-in-class" therapies are distinguished not just by efficacy, but by innovations in formulation and delivery that improve the patient experience. Examples include subcutaneous versions of IV drugs and new delivery methods that expand patient access.

Subcutaneous on-body device delivery of anti-CD38 antibodies like isatuximab nearly eliminates the high risk of infusion-related reactions common with intravenous administration, especially during the first dose. This significantly enhances patient safety and comfort in the clinic.